HCPLive
64th American Academy of Neurology Annual Meeting

Related Tags

AAN 2012: Interview with Dr. Zigmond about Exercise and Parkinson’s Disease Study [Podcast]

In this interview, Michael Zigmond, PhD, Professor of Neurology at theUniversity of Pittsburgh, discusses why he became involved with studying Parkinson’s disease and his research on exercise and Parkinson’s disease which he will be presenting at this year's AAN conference.

When asked about how he began his research in Parkinson's disease, Zigmond said, "I became interested in catecholamines, which includes dopamine and norepinephrine primarily, as a graduate student. There was evidence that they were affected by stress and I was interested in looking at the adaptive effects of stress."

It was upon collaborating with colleague when Zigmond explained how he "discovered that... physicial exercise was what we would call 'neuroprotective.' If you had animals exercise before you expose them to a toxin like 6-Hydroxydopamine, the effects of the toxin on the animals' behavior and on the dopamine neurons themselves was reduced."


 

Most Popular

Recommended Reading

For patients with Alzheimer's Disease, as their condition worsens it often falls on other members of their family to make decisions about their course of treatment. What they are expected to do and how they make certain decisions can have long lasting impacts on the care of the people with the disease.
One of the main focus points in the treatment of Alzheimer's Disease is screening patients before they even show symptoms of the condition. This is a part of the process that also includes looking to develop new treatments that could be used in the future.
While Alzheimer's Disease is not a new condition, finding a treatment has been elusive even as more is learned about it. Part of the diagnosis involves knowing what to look for beyond tests of cognition and other aspects of a patient's life.
Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.
$vAR$